This document is a publication of a European patent application (EP4039703A1) by Helixmith Co., Ltd. The patent describes a Chimeric Antigen Receptor that includes an anti-C-Met antibody or an antigen binding fragment thereof, and its potential uses. The publication date is March 11, 2026.

As this is a patent publication, it does not impose direct regulatory obligations or compliance deadlines on regulated entities. However, it may be relevant for companies involved in the development of cancer therapies, particularly those utilizing CAR-T technology or targeting the C-Met receptor, for intellectual property considerations and competitive landscape analysis.